Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

RenJi Hospital · 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
fumarate hydratase deficient renal cell carcinoma, pd-1 checkpoint inhibitor, fhrcc, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 917857
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.